Recent Updates
-
New Features of SOAPware 2011
-
NQF 0047 - (Additional) Asthma Pharmacologic Therapy
<p>Measure: NQF 0047</p> <p>Measurement Title: Asthma Pharmacologic Therapy</p> <p>Measure Description: Percentage of patients aged 5 through 40 years with a diagnosis of mild, moderate, or severe persistent asthma who were prescribed either the preferred longāterm control medication (inhaled ... -
NQF 0089 - (Additional) Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
<p>Measure: NQF 0089 (Additional Measurement)</p> <p>Measure: Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care </p> <p>Measure Description: Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or f... -
NQF 0088 - (Additional) Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
<p>Measure: NQF 0088 (Alternate Core Measurement)</p> <p>Measure Title: Diabetic Retinopathy: Documentation of presence or absence of macular rdema and level of Severity of Retinopathy </p> <p>Measure Description: Percentage of patients aged 18 years and older with a diagnosis of diabetic ret... -
NQF 0083 (Additional) Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
<p>Measure: NQF 0083 (Additional Measure)</p> <p>Measure Title: Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)</p> <p>Measurement Description: Percentage of patients aged 18 years and older with a diagnosis of heart failure who also have LVSD (LVEF &l... -
NQF 0086 - (Additional) Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
<p>Measure: NQF 0086 (Additional Measurement)</p> <p>Measure Title: Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation</p> <p>Measure Description: Percentage of patients aged 18 years and older with a diagnosis of POAG who have been seen for at least 2 office visits, who have an optic ... -
(DRAFT) *NQF 0105 - (Additional) Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
Updated on: Dec 07, 2022
<p>THIS LESSON IS CURRENTLY A DRAFT AND IS NOT YET COMPLETE.</p> <p>Measure: NQF 0105 (Additional Measurement)</p> <p>Measure: Anti-depressant medication management: (a) Effective Acute Phase Treatment, (b)Effective Continuation Phase Treatment </p> <p>Measure Description: The percentage of pa... -
NQF 0031 (Additional): Breast Cancer Screening
<p>Measure: NQF 0031 (Additional Measure)</p> <p>Measure Title: Breast Cancer Screening</p> <p>Measure Description: Percentage of women 40-69 years of age whom had a mammogram to screen for breast cancer</p> <p>*REQUIRED FOR MEANINGFUL USE (MU) ADDITIONAL CQM MEASURE: Click here to view Meanin... -
Record of Disclosures
Updated on: Dec 07, 2022
<p>This lesson will demonstrate the necessary steps to meet the Meaningful Use requirement for Record of Disclosures.</p> <p>*REQUIRED FOR MEANINGFUL USE: CLICK HERE TO VIEW THE MEANINGFUL USE ROADMAP <br />- OR Protect Electronic Health Information</p> <p>*Note: Please download the following d... -
NQF 0067 (Additional) Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
<p>Measure: NQF 0067</p> <p>Measure Title: Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD</p> <p>Measure Description: Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed oral antiplatelet therapy.</p> <p>*REQU...